Study of SNH-118110 in Advanced Solid Tumors

Summary

This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally. The study consists of a dose-escalation phase and a dose-expansion phase.

Timeline

Start

2026-06-26

Primary completion

2027-06-26

Completion

2029-06-26

Drugs

Indications